Pharma Sector

According to the company, the parties will sign a commercial supply agreement under which Ingenus will deliver the product to Dr. Reddy's USA.

Gland Pharma said that its consolidated profit after tax (PAT) increased more than twofold to ₹192 Crore in the March quarter.

The availability of P-CABs such as Kabvie will allow the Indian people to access innovative and effective GERD treatments.

Biocon's consolidated net profit decreased by 57% to ₹136 Crore in the fourth quarter of March 2024 due to increased expenses.

In addition, Aurobindo Pharma will spend ₹1,000 Crore to establish a biologics manufacturing facility in Borapatla, Telangana.

According to reports, the USFDA made various observations concerning Sun Pharma. First, the company did not take appropriate safeguards to avoid API contamination.

According to a business announcement, net profit increased by 79% to ₹909 Crore in the fourth quarter of FY24, from ₹506 Crore in the same period in FY23.

The total net profit for the fiscal year ended March 31, 2024 was ₹1,656 Crore, up from ₹1,245 Crore the previous year, according to the business.

The net profit and EBITDA margin excluding ex-Cenexi, a contract manufacturing firm that Gland acquired for more than ₹1,000 Crore last year.

AVT03 is a human monoclonal antibody and a biosimilar contender for Prolia and Xgeva, both of which contain denosumab.